In the BioHarmony Drug Report Database

"Preview" Icon

Ranibizumab

Lucentis (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.

 

Trade Name

 

Lucentis
 

Common Name

 

ranibizumab
 

ChEMBL ID

 

CHEMBL1201825
 

Indication

 

degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, retinal vein occlusion, wet macular degeneration
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Ranibizumab structure rendering